KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Accumulated Expenses for 16 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 36.1% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 36.1%, and an annual FY2025 reading of $1.1 billion, up 36.1% over the prior year.
  • Accumulated Expenses was $1.1 billion for Q4 2025 at Alnylam Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.2 billion in Q3 2025 and bottomed at $280.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $643.8 million, with a median of $648.7 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses skyrocketed 61.56% in 2021, then rose 0.76% in 2025.
  • Year by year, Accumulated Expenses stood at $395.2 million in 2021, then skyrocketed by 38.03% to $545.5 million in 2022, then skyrocketed by 30.72% to $713.0 million in 2023, then rose by 11.32% to $793.7 million in 2024, then surged by 36.1% to $1.1 billion in 2025.
  • Business Quant data shows Accumulated Expenses for ALNY at $1.1 billion in Q4 2025, $1.2 billion in Q3 2025, and $919.0 million in Q2 2025.